Abstract 3202
Background
Patient access to clinical trials is a fundamental aspect of drug development, particularly phase 1 oncology trials recruiting patients with advanced cancers. Adequate representation of both male and female patients in early phase trials is necessary to determine the impact of gender on safety, pharmacokinetics, and other parameters evaluated. Underrepresentation of women in oncology clinical research has been demonstrated in the past. We sought to determine whether a similar trend exists in phase 1 clinical trials.
Methods
All phase 1 trials published in the Journal of Clinical Oncology (JCO) between 2010 – 2018 were reviewed and the following parameters determined: patient population; total number of participants; number and percentage of Male and Female participants. To ensure reliability, two independent reviews were conducted. This abstract focused on the subset of studies targeting a population of adult and pediatric non-tumor specific advanced cancer patients with no treatment options for their disease. The expected representation of male and female patients within this population was assumed to be 1:1. The absolute difference in percentage between 50% and the observed percentage of patients who were male and female was calculated.
Results
73 phase 1 clinical trials were published in JCO reviewed including 3,855 patients. 4 trials did not report the male/female distribution and were excluded from the analysis. 27 (37%) studies were conducted in a population of advanced cancer patient, including 1,719 patients. The average absolute percentage difference between the expected and observed population was +2% for the male population and -4% for the female population. Wilcox Signed Rank Test demonstrated borderline statistical significance of this result (0=0.058).
Conclusions
Based on a cohort of 27 phase 1 studies published in JCO, it appears that underrepresentation of women in oncology clinical trials extends to phase 1 clinical development. It may be necessary for oncology phase 1 protocols to address the issue of adequate gender representation within the patient population enrolled. Attention should be given to identifying the barriers for women participation in trials to ensure adequate patient access, and representation in this critical stage of drug development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Syneos Health.
Funding
Syneos Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract